Literature DB >> 12941892

Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.

Lia M Haynes1, Les P Jones, Albert Barskey, Larry J Anderson, Ralph A Tripp.   

Abstract

Vaccination with formalin-inactivated respiratory syncytial virus (FI-RSV) vaccine or RSV G glycoprotein results in enhanced pulmonary disease after live RSV infection. Enhanced pulmonary disease is characterized by pulmonary eosinophilia and is associated with a substantial inflammatory response. We show that the absence of the G glycoprotein or G glycoprotein CX3C motif during FI-RSV vaccination or RSV challenge of FI-RSV-vaccinated mice, or treatment with anti-substance P or anti-CX3CR1 antibodies, reduces or eliminates enhanced pulmonary disease, modifies T-cell receptor Vbeta usage, and alters CC and CXC chemokine expression. These data suggest that the G glycoprotein, and in particular the G glycoprotein CX3C motif, is key in the enhanced inflammatory response to FI-RSV vaccination, possibly through the induction of substance P.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12941892      PMCID: PMC224581          DOI: 10.1128/jvi.77.18.9831-9844.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  76 in total

Review 1.  Chemokines: attractive mediators of the immune response.

Authors:  Mark M Wong; Eleanor N Fish
Journal:  Semin Immunol       Date:  2003-02       Impact factor: 11.130

Review 2.  Immunological determinants of disease caused by respiratory syncytial virus.

Authors:  B S Graham
Journal:  Trends Microbiol       Date:  1996-07       Impact factor: 17.079

3.  C-C chemokine-induced eosinophil chemotaxis during allergic airway inflammation.

Authors:  N W Lukacs; T J Standiford; S W Chensue; R G Kunkel; R M Strieter; S L Kunkel
Journal:  J Leukoc Biol       Date:  1996-11       Impact factor: 4.962

4.  Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population.

Authors:  J Chin; R L Magoffin; L A Shearer; J H Schieble; E H Lennette
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

5.  Respiratory virus vaccines. VII. Field evaluation of respiratory syncytial, parainfluenza 1, 2, 3, and Mycoplasma pneumoniae vaccines, 1965 to 1966.

Authors:  R E Weibel; J Stokes; M B Leagus; C C Mascoli; A A Tytell; A F Woodhour; P P Vella; M R Hilleman
Journal:  Am Rev Respir Dis       Date:  1967-10

6.  Generation of atypical pulmonary inflammatory responses in BALB/c mice after immunization with the native attachment (G) glycoprotein of respiratory syncytial virus.

Authors:  G E Hancock; D J Speelman; K Heers; E Bortell; J Smith; C Cosco
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

Review 7.  Immunopathological mechanisms in respiratory syncytial virus disease.

Authors:  P J Openshaw
Journal:  Springer Semin Immunopathol       Date:  1995

Review 8.  Pathogenesis of respiratory syncytial virus vaccine-augmented pathology.

Authors:  B S Graham
Journal:  Am J Respir Crit Care Med       Date:  1995-10       Impact factor: 21.405

9.  Loss of conserved cysteine residues in the attachment (G) glycoprotein of two human respiratory syncytial virus escape mutants that contain multiple A-G substitutions (hypermutations).

Authors:  P Rueda; B García-Barreno; J A Melero
Journal:  Virology       Date:  1994-02       Impact factor: 3.616

10.  Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine.

Authors:  V A Fulginiti; J J Eller; O F Sieber; J W Joyner; M Minamitani; G Meiklejohn
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

View more
  55 in total

1.  Prophylactic treatment with a G glycoprotein monoclonal antibody reduces pulmonary inflammation in respiratory syncytial virus (RSV)-challenged naive and formalin-inactivated RSV-immunized BALB/c mice.

Authors:  Gertrud U Radu; Hayat Caidi; Congrong Miao; Ralph A Tripp; Larry J Anderson; Lia M Haynes
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

2.  Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Authors:  Yoshihiko Murata; Seana C Catherman
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

Review 3.  Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy--a review.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2006-10       Impact factor: 2.332

4.  Th17 cytokines are critical for respiratory syncytial virus-associated airway hyperreponsiveness through regulation by complement C3a and tachykinins.

Authors:  Monali M Bera; Bao Lu; Thomas R Martin; Shun Cui; Lawrence M Rhein; Craig Gerard; Norma P Gerard
Journal:  J Immunol       Date:  2011-09-14       Impact factor: 5.422

5.  CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells.

Authors:  Tatiana Chirkova; Songbai Lin; Antonius G P Oomens; Kelsey A Gaston; Seyhan Boyoglu-Barnum; Jia Meng; Christopher C Stobart; Calvin U Cotton; Tina V Hartert; Martin L Moore; Assem G Ziady; Larry J Anderson
Journal:  J Gen Virol       Date:  2015-06-25       Impact factor: 3.891

6.  C5 modulates airway hyperreactivity and pulmonary eosinophilia during enhanced respiratory syncytial virus disease by decreasing C3a receptor expression.

Authors:  Guillermina A Melendi; Scott J Hoffman; Ruth A Karron; Pablo M Irusta; Federico R Laham; Alison Humbles; Brian Schofield; Chien-Hsiung Pan; Richard Rabold; Bhagvanji Thumar; Adeep Thumar; Norma P Gerard; Wayne Mitzner; Scott R Barnum; Craig Gerard; Steven R Kleeberger; Fernando P Polack
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Serum mannose-binding lectin levels are linked with respiratory syncytial virus (RSV) disease.

Authors:  Lucas Zimon Giacomini Ribeiro; Ralph A Tripp; Lívia Maria Gonçalves Rossi; Patrícia Vianna Bonini Palma; Jonny Yokosawa; Orlando Cesar Mantese; Thelma Fátima Mattos Oliveira; Lysa Luiz Nepomuceno; Divina Aparecida Oliveira Queiróz
Journal:  J Clin Immunol       Date:  2007-10-20       Impact factor: 8.317

8.  A recombinant influenza virus vaccine expressing the F protein of respiratory syncytial virus.

Authors:  Wendy Fonseca; Makoto Ozawa; Masato Hatta; Esther Orozco; Máximo B Martínez; Yoshihiro Kawaoka
Journal:  Arch Virol       Date:  2013-12-01       Impact factor: 2.574

9.  Recombinant parainfluenza virus 5 vaccine encoding the influenza virus hemagglutinin protects against H5N1 highly pathogenic avian influenza virus infection following intranasal or intramuscular vaccination of BALB/c mice.

Authors:  Alaina J Mooney; Zhuo Li; Jon D Gabbard; Biao He; S Mark Tompkins
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

10.  Prophylaxis with a respiratory syncytial virus (RSV) anti-G protein monoclonal antibody shifts the adaptive immune response to RSV rA2-line19F infection from Th2 to Th1 in BALB/c mice.

Authors:  Seyhan Boyoglu-Barnum; Tatiana Chirkova; Sean O Todd; Thomas R Barnum; Kelsey A Gaston; Patricia Jorquera; Lia M Haynes; Ralph A Tripp; Martin L Moore; Larry J Anderson
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.